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Obstructive sleep apnea (OSA) is a common disorder associated with an increased risk of
cardiovascular disease and stroke. As it is strongly associated with known cardiovascular risk
factors, including obesity, insulin resistance, and dyslipidemia, OSA is an independent risk
factor for hypertension and has also been implicated in the pathogenesis of congestive cardiac
failure, pulmonary hypertension, arrhythmias, and atherosclerosis. Obesity is strongly linked
to an increased risk of OSA, and weight loss can reduce the severity of OSA. The current
standard treatment for OSA—nasal continuous positive airway pressure (CPAP)—eliminates
apnea and the ensuing acute hemodynamic changes during sleep. Long-term CPAP
treatment studies have shown a reduction in nocturnal cardiac ischemic episodes and
improvements in daytime blood pressure levels and left ventricular function. Despite the
availability of effective therapy, OSA remains an underdiagnosed and undertreated condition.
A lack of physician awareness is one of the primary reasons for this deficit in diagnosis and
treatment. (J Am Coll Cardiol 2003;41:1429–37) © 2003 by the American College of
Cardiology Foundation
Obstructive sleep apnea (OSA) is the most common form of
sleep-disordered breathing, affecting thousands of patients
each year in the U.S. alone (1,2). It is characterized by
repetitive partial or complete closure of the upper airway
during sleep. Acute physiologic stresses occur during these
episodes of asphyxia, including arterial oxygen desaturation,
surges in sympathetic activity, and acute hypertension. In a
patient with moderate-to-severe OSA, these cycles may
occur hundreds of times a night.
Descriptions of sleep-disordered breathing date back
nearly 200 years (3), but only in the past 20 years have
treatment options made diagnosis and intervention a prior-
ity (4). The association between OSA and cardiovascular
disease was first raised by observational studies linking
snoring, a surrogate for OSA, with increased cardiac events
(5). Subsequent studies have demonstrated a clear relation-
ship between the presence and severity of OSA and both
systemic hypertension and increased cardiovascular disease
(6–8). Currently, OSA is thought to play a role in the
pathogenesis of systemic hypertension and congestive car-
diac failure, as well as possibly acute coronary syndromes,
pulmonary hypertension (PHT), arrhythmias, and cerebro-
vascular events (9). This review focuses on the epidemiology
and diagnosis of sleep apnea, its potential role in the
pathogenesis of cardiovascular disease, and the relationship
between successful management and improved outcomes.
EPIDEMIOLOGY AND DIAGNOSIS OF OSA
Obstructive sleep apnea is part of a spectrum of sleep-
related breathing disorders that includes snoring, upper
airway resistance syndrome (increased respiratory effort
without apnea or hypopnea), and central sleep apnea (CSA)
(apnea without respiratory effort). The OSA syndrome is
the combination of obstructive apneas with daytime tired-
ness or recurrent awakenings or gasping episodes (10).
Initial descriptions of OSA were of severe apnea in obese,
middle-age male patients (11,12). It is now appreciated,
however, that women account for one-third of OSA pa-
tients (13), and a normal body mass index (BMI) is
common, particularly in subjects who are elderly (14) or
from Southeast Asia (15).
Clinical suspicion of OSA is usually raised by complaints
of snoring and daytime tiredness, despite an adequate
duration of sleep. Mainly, OSA patients are managed
clinically by sleep physicians with a background in respira-
tory medicine or neurology. Atypical presentations are not
uncommon, however, and result in OSA patients presenting
to a variety of medical specialists. Indeed, many OSA
patients remain asymptomatic from their apneas, presenting
instead with hypertension, arrhythmias, or congestive car-
diac failure to a cardiologist (Table 1).
Polysomnography is the “gold standard” diagnostic tool
for assessing sleep-disordered breathing. It requires an
overnight stay at a sleep laboratory, with monitoring of
oxygen saturation, heart rate, sleep stage by electroencepha-
lography, nasal airflow, oral airflow, jaw muscle tone by
electromyography, sleep position, and chest and abdominal
movement. Measurement of these parameters allows diag-
nosis of the type of sleep-disordered breathing and its
severity. The apnea-hypopnea index (AHI)—the number of
obstructive events per hour—is the most commonly used
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measurement to quantify OSA: mild OSA  5 to 15
events/h; moderate  15 to 30 events/h; and severe  30
events/h (10). A “negative” polysomnographic study does
not exclude mild OSA, however, because there is night-to-
night variability in the frequency of obstructive events
(Fig. 1).
Estimates of the prevalence of OSA have shown a wide
variance depending on the methodology used. However,
three large-scale studies using polysomnography have re-
ported similar prevalence estimates for OSA (16–18). The
Wisconsin Sleep Cohort Study showed that 25% of middle-
age men and 10% of middle-age women had sleep-
disordered breathing (AHI 5/h), with 4% of men and 2%
of women also having hypersomnolence, fulfilling the cur-
rent diagnostic criteria for the sleep apnea syndrome (16).
Recently, alternative methods of screening for OSA have
become available, which allow for home-sleep assessments.
The most advanced of these devices records respiratory
effort, desaturation, airway obstruction, and sleep stage.
Arterial oxygen saturation alone is not an effective screening
tool, as the majority of patients with mild OSA have few
desaturations (19). In the future, simpler and cheaper
methods of diagnosis of sleep-disordered breathing will help
improve diagnosis in this under-recognized condition.
VASCULAR DISEASE AND OSA
Sleep apnea and hypertension. Obstructive sleep apnea is
now recognized to be an independent risk factor for daytime
hypertension. An association between OSA and hyperten-
sion was suggested by a series of population and cohort
studies, observational studies in patients attending hyper-
tension clinics and sleep clinics (20,21). A recent sleep clinic
study reported a linear relationship between hypertension
and severity of OSA, with each extra apneic episode per
hour increasing the odds of hypertension by 1% (22).
Increased variability of blood pressure and loss of the
nocturnal blood pressure dip were also reported (23). In the
large Sleep Heart Health Study, 6,132 middle-age subjects
had unattended (no technician was present) home, full
polysomnographic studies; adjusting for confounders re-
sulted in an odds ratio (OR) of 1.37 (95% confidence
interval [CI] 1.03 to 1.83) for hypertension, between the
highest and lowest categories of AHI (24).
Prospective confirmation of the association was reported
by the Wisconsin Sleep Cohort Study, which measured the
incidence of hypertension over a four- to eight-year
follow-up in 709 subjects. The AHI was a significant
independent predictor of daytime hypertension, with an OR
of 2.89 (95% CI 1.46 to 5.64) for those with AHI 15/h
and no evidence of a threshold below which the association
did not hold (25). The implications of this study are
profound, indicating that OSA is a new primary cause of
hypertension (Fig. 2).
Treatment of OSA with nasal continuous positive airway
pressure (CPAP) has led to falls in office, intra-arterial (26),
and ambulatory blood pressure (27) in small, nonrandom-
ized studies. Also, CPAP reduces the sympathetic nervous
system activation associated with apneas (Fig. 3). A recent
prospective, randomized, placebo-controlled comparison
between therapeutic and subtherapeutic CPAP reported a
reduction in blood pressure, particularly in those with more
severe OSA (28).
Sleep apnea and risk factors for atherosclerosis. Patients
with OSA have many features in common with the “met-
abolic syndrome,” including systemic hypertension, central
obesity (29), and insulin resistance (30). The AHI correlates
with BMI, waist-to-hip ratio, hypertension, and diabetes,
whereas trends toward lower high-density lipoprotein and
elevated triglycerides are reported for OSA subjects 65
years old (14). Although the association between OSA and
the metabolic syndrome is, to a large extent, mediated by
obesity, AHI remains an independent predictor of insulin
resistance, even after correcting for BMI (31).
In a controlled study of patients with type II diabetes and
OSA treated with nasal CPAP, Brooks et al. (32) showed
improved insulin sensitivity, while weight and drug treat-
ment remained stable. One possible mechanism by which
OSA might increase insulin resistance is through increased
sympathetic nerve activity, demonstrated to occur not only
Abbreviations and Acronyms
AHI  apnea-hypopnea index
BMI  body mass index
CI  confidence interval
CPAP  continuous positive airway pressure
CSA  central sleep apnea
OR  odds ratio
OSA  obstructive sleep apnea
PHT  pulmonary hypertension
RR  relative risk
Table 1. Clinical Evaluation
Symptoms
Loud snoring
Choking or gasping episodes
Tiredness on waking
Excessive daytime sleepiness
Poor concentration and short-term memory
Associated clinical findings
Increased body mass index
Increased neck circumference
Small erythematous oropharynx
Systemic hypertension
Congestive cardiac failure
Pulmonary hypertension
Cor pulmonale
Atypical presentations
Nocturnal palpitations
Morning headaches
Seizures
Gastroesophageal reflux
Nocturia
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Figure 1. Polysomnography: an overnight summary. The graphs from the top are: 1) hypnogram: the sleep stage report (MOV AWK  movement when
awake; REM  rapid eye movement; 1 to 4  non-rapid eye movement sleep); 2) arousals: each is a single mark; 3) SaO2  percentage oxygen saturation;
4) apnea score: each is a single mark (Cn.A  central apnea; Ob.A  obstructive apnea; Mx.A  mixed apnea; Hyp  hypopnea; Uns  unscored); 5)
PLMs  paroxysmal limb movements; 6) heart rate versus time (beats/minute); 7) body position; this subject remained on his back throughout the study;
and 8) time (h).
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at night but also during the day; such activity is reduced by
CPAP treatment.
Although the association between OSA and the meta-
bolic syndrome tends to confound studies of the indepen-
dent effects of OSA on vascular disease, increased awareness
of this association should enhance recognition of patients
likely to have OSA (Fig. 4) (33).
ACUTE CORONARY AND
CEREBROVASCULAR SYNDROMES
Sleep apnea and acute cardiovascular events. The risk of
experiencing angina or an acute coronary syndrome is
increased in the hours after waking from sleep. In OSA,
cyclical variations in heart rate and blood pressure are
dramatic (26), more so than many hemodynamic stresses in
daily life, and occur during sleep, a time when in normal
subjects blood pressure and heart rate are the lowest and
least variable. In OSA, increased peripheral sympathetic
nerve activity during sleep persists during wakefulness at
approximately twice the normal levels (34) and may affect
acute coronary events in the early hours of the day.
Early epidemiologic studies suggested an association
between snoring and myocardial infarction in men (35). In
a subsequent community study when confounding variables
were accounted for, the OR for increased coronary disease
was reduced but remained significant at 1.4 (95% CI 0.4 to
4.5) (36).
A tightly matched case-control study of acute coronary
care patients confirmed OSA as an independent predictor of
coronary artery disease, with an OR of 3.1 (7). At long-term
follow-up, subjects with coronary artery disease whose OSA
remained untreated had worse mortality (37).
Whether there is a relationship between nocturnal OSA
and ischemia remains controversial. A randomly selected
group of 226 patients having coronary angiography investi-
gated with an overnight sleep study and Holter monitoring
demonstrated frequent episodes of nocturnal ischemia, but
this had only limited correlation with sleep-disordered
breathing (8). Previous smaller studies of patients with
moderate-to-severe OSA reported relatively high incidences
of nocturnal ischemia (38–40).
Stroke. Strong evidence of a link between snoring and
stroke now exists from case-control studies and the Nurses
Health Study (41–44); after eight-year follow-up, there was
an age-adjusted relative risk (RR) of stroke of 1.6 (95% CI
1.21 to 2.12) for occasional snorers and 1.88 (95% CI 1.62
to 2.53) for regular snorers. The BMI and covariate correc-
tions removed the significance of regular snoring, suggesting
the effect is partly mediated by obesity, but statistical
significance remained for occasional snorers (RR 1.42, 95%
CI 1.07 to 1.89) (45).
Mechanisms by which OSA may precipitate stroke in-
clude hypertension, mechanical stress on carotid atheroma
during the snoring phase of cyclical apneas, altered cerebral
perfusion (46,47), increased coagulability (48,49), and/or
induction of atrial arrhythmias with thrombus formation
leading to embolism.
Arrhythmias. Both tachyarrhythmias and bradyarrhyth-
mias have been implicated as possible causes of cardiovas-
cular morbidity in OSA patients. The risk of arrhythmia
with OSA appears to be related to sleep apnea severity.
Analysis of electrocardiographic recordings in 458 patients
having sleep studies showed a 58% prevalence of arrhyth-
mias in patients with OSA, compared with 42% in nonap-
neics, most arrhythmias occurring in those with AHI
40/h (50).
The role of sleep-disordered breathing in arrhythmias in
heart failure is still being defined. In a study of 81 males
with stable heart failure, incidences of atrial fibrillation and
ventricular tachycardia were significantly higher in sleep
apnea subjects (AHI 10/h) than in those without apnea
(51).
One small, prospective study showed that CPAP reduced
premature ventricular contractions and couplets in OSA
patients with normal left ventricular function (52). In a
small but intriguing study (53), atrial pacing reduced the
severity of OSA based on AHI. However, the mechanism
by which this might have been achieved is unclear; reflex
effects on upper airway tone represent one possible expla-
nation.
HEART FAILURE AND OSA
Obstructive sleep apnea is common in heart failure patients.
Javaheri et al. (51) performed polysomnography on 81 males
with stable heart failure, identifying 11% with OSA. De-
spite only one-quarter of this group reporting tiredness, over
one-half had some form of sleep-disordered breathing, with
Figure 2. Dose-response relationship between the severity of obstructive
sleep apnea based on apnea-hypopnea index and the adjusted odds ratio of
hypertension, defined as blood pressure 140/90 mm Hg or current
treatment with antihypertensive medications. Odds ratio was adjusted for
baseline hypertension status, age, gender, habitus, and weekly alcohol and
cigarette use. p  0.002 for linear trend of the logistic regression
coefficients. Data from Peppard et al. (25).
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CSA in 40%. Central sleep apnea differs from OSA in that
there is periodic cessation of breathing with no respiratory
effort, followed by hyperventilation. The key mechanisms of
periodic breathing in heart failure patients are enhanced
chemoreflex sensitivity, hypocapnia, and unstable breathing
control, especially during sleep (54,55).
Patients with heart failure can have a combination of
CSA and OSA, which can vary during sleep or over time. In
one study, within-night changes were documented with
progression from predominantly OSA early in the night to
CSA, presumably due to the fall in the arterial pCO2 level
to below the apneic threshold (56).
A diagnosis of sleep-disordered breathing provides im-
portant prognostic information and potential therapeutic
options for heart failure patients (57). The frequency of
apnea is highly predictive of mortality, with AHI 30/h,
providing prognostic information over and above New York
Heart Association functional class and left ventricular ejec-
tion fraction (58). Treatment of OSA with CPAP improves
quality of life, but no published study has been adequately
powered to show a mortality benefit (59).
Echocardiographic studies have shown both systolic (60)
and diastolic (61) dysfunction with increasing AHI. Possi-
ble mechanisms include the effects of hypoxia (62) and the
Figure 3. Sympathetic nerve activity increases through the obstructive apnea, resulting in marked vasoconstriction followed by increased systolic and
diastolic blood pressure. Continuous positive airway pressure (CPAP) stabilizes both sympathetic activity and blood pressure surges. BP  blood pressure
(mm Hg); OSA obstructive sleep apnea; REM rapid eye movement; RESP respiration; SNA sympathetic nerve activation. Adapted from Somers
et al. (67) with permission.
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repetitive intrathoracic pressure changes that accompany
obstructive apneas. Negative intrathoracic pressure increases
left ventricular afterload (63), as well as impairs left ventric-
ular relaxation (64). Cardiac contractility is also reduced and
left ventricular volumes rise, both at end-systole and end-
diastole (65). Hypoxia itself may directly impair the energy-
dependent processes of myocyte contraction and relaxation
(66). Activation of the sympathetic nervous system, by both
hypoxia and arousal, may induce tachycardia and peripheral
vasoconstriction, further increasing ventricular afterload
(67).
Pulmonary hypertension. Acute pulmonary hemodynamic
changes during obstructive apneas have been well defined,
but the extent to which these translate into permanent
daytime PHT remains less certain than in the systemic
circulation. Sustained daytime PHT in OSA subjects has
been investigated in several studies, the majority of which
have found an increased prevalence of PHT (68–70).
The largest confounding group, however, is patients with
chronic obstructive pulmonary disease (“overlap” syn-
drome). Only three published studies have excluded patients
with this disease; their PHT prevalence results are 20% (71),
41% (69), and 27% (72), respectively. No correlation was
found in these studies between the severity of PHT and
AHI. Nocturnal desaturation, however, was linked with
daytime PHT.
OSA SCREENING AND
MANAGEMENT: A CARDIOLOGIST’S PERSPECTIVE
Establishing the diagnosis. The majority of individuals
with OSA and vascular disease remain undiagnosed, largely
due to limited physician awareness of this association (Fig.
5) (1). All patients with hypertension, obesity, or heart
failure should be asked routinely about OSA and referred
for a sleep study if they are symptomatic (Table 2). Simple
screening questions such as “Do you snore?,” “Are you tired
on waking?,” or “Do you fall asleep during the day?” will
identify the majority of patients with significant OSA. The
Epworth Sleep Scale standardizes these questions by pro-
viding a rapid, validated method of screening for tiredness
and is useful in both clinical practice and research settings
(Table 1) (10).
Treatment. For obese subjects, including those with the
metabolic syndrome, weight loss is a cornerstone of therapy,
not only by reducing AHI, though seldom to normal, but
also by improving hypertension, lipid metabolism, and
insulin resistance. Patients with a normal BMI, severe OSA
at diagnosis, or those having difficulty losing weight require
specific treatment of OSA, such as nasal CPAP or an oral
appliance.
The mainstay of OSA therapy for the past 20 years has
Table 2. Epworth Sleepiness Scale
Situation
Sitting and reading
Watching TV
Sitting in an inactive place (e.g., movie)
As a passenger in a car without a break for an hour
Lying down to rest in the afternoon when the circumstances permit
Sitting and talking to someone
Sitting quietly after lunch without alcohol
In a car, while stopped for a few minutes
Scale Score
No chance of dozing 0
Slight 1
Moderate 2
High 3
(Score for each situation is added to total)
Total
6  Less tired than average
7–8  Average
9  Tiredness requiring investigation
Figure 4. Schema illustrating the risk factor clustering of obstructive sleep
apnea (OSA) and the proposed links to both acute and chronic vascular
disease. Solid line  proven risk factor; dashed line  potential risk
factor.
Figure 5. Prevalence of obstructive sleep apnea (OSA) in patients with
cardiovascular and cerebrovascular disease. The figures used are approxi-
mations from published data and are unadjusted for baseline variables (1 to
4): 1. Parati G, Ongaro G, Bonsignore MR, Glavina F, Di Rienzo M,
Mancia G. Sleep apnoea and hypertension. Curr Opin Nephrol Hypertens
2002;11:201–14; 2. Sin DD, Fitzgerald F, Parker JD, Newton G, Floras
JS, Bradley TD. Risk factors for central and obstructive sleep apnea in 450
men and women with congestive heart failure. Am J Respir Crit Care Med
1999;160:1101–6; 3. Bassetti C, Aldrich MS. Sleep apnea in acute
cerebrovascular diseases: final report on 128 patients. Sleep 1999;22:217–
23; and 4. Peker Y, Kraiczi H, Hedner J, Loth S, Johansson A, Bende M.
An independent association between obstructive sleep apnoea and coronary
artery disease. Eur Respir J 1999;14:179–84.
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been nasal CPAP (4). This treatment maintains a patent
airway during sleep by splinting the airway with positive
pressure applied through a nasal mask, eliminating apneas,
sleep fragmentation, and consequent hemodynamic
changes. Although CPAP is an effective treatment of OSA,
compliance can be a problem, even in patients with severe
symptomatic OSA. Some patients do not tolerate the
therapy, and others find purchasing a machine financially
prohibitive. Early follow-up when commencing CPAP
therapy, therefore, is important. Common concerns raised
when initiating CPAP therapy include nasal congestion or
dryness, which can usually be overcome with a humidifier,
and abrasions or mask leak, which respond to local mea-
sures. Nursing support and intensive education programs
have also been shown to improve compliance (73).
Follow-up studies indicate, on average, 4 h of effective
CPAP is administered per night, and even this amount of
CPAP treatment improves daytime tiredness (74).
The latest development in CPAP treatment is automated
CPAP (75). These devices determine the pressure require-
ments for each breath. Improved tolerability is particularly
noticeable in patients who wake frequently, those with body
position-dependent and rapid eye movement-related OSA
(76). Detailed data logging of compliance and air leak by
these devices also allows monitoring of the effectiveness of
treatment.
Alternative treatments for OSA in patients who cannot
tolerate CPAP include mandibular advancement splints and
surgical interventions. Caution is necessary when prescrib-
ing these therapies, as apneas are rarely completely averted
and less information is available on their effectiveness,
particularly in patients with cardiac failure. In extreme
situations where OSA is severe and CPAP is not tolerated,
tracheostomy will cure OSA (77).
Who to treat? Treatment of OSA to relieve symptoms of
daytime tiredness and to avoid somnolence-induced motor
vehicle and work-related accidents is an established practice
(78). Recently there has been increased interest in the role of
CPAP to prevent cardiovascular disease and aid in control-
ling hypertension. Evidence for a dose-response relationship
between AHI and daytime hypertension is strong, and small
studies have shown improvements in blood pressure (27,79),
baroreceptor sensitivity (80), and nitric oxide derivative
production (81), and a reduction in sympathetic nervous
system activation (67,82,83) with treatment of OSA.
In heart failure patients, CPAP provides symptomatic
relief and reduces the need for intubation during acute
exacerbations (84). Small trials have demonstrated improved
quality of life (85) and exercise capacity (86) with CPAP
therapy. Improved left ventricular ejection fraction has also
been reported, with deterioration in left ventricular ejection
fraction on withdrawal of therapy (87). Mechanisms by
which CPAP therapy exerts its beneficial effect may include
reductions in left ventricular afterload (88) and sympathetic
nerve activity (82). Currently, the Canadian Continuous
Positive Airway Pressure Trial for Congestive Heart Failure
Patients with Central Sleep Apnea (CANPAP) is under-
way, with the aim of further defining the role of CPAP in
heart failure therapy (89).
Arrhythmia reduction (52,90) and improved PHT (91)
have also been reported with CPAP. For many cardiovas-
cular events, including acute coronary syndromes and sud-
den death, however, no treatment studies are available, so
treatment decisions must be made empirically.
FUTURE DIRECTIONS
Much data suggest that OSA is a novel cardiovascular
disease risk factor; however, it will take a series of carefully
conducted pathophysiological and clinical studies to bridge
these gaps in our knowledge in this area. Sleep apnea has
clearly been demonstrated to be an independent risk factor
for hypertension. More importantly, all published studies
have shown that a large proportion (40% to 80%) of stroke
patients have OSA, suggesting it may increase the stroke
risk beyond direct effects on blood pressure level and
variability.
We have also to review, and perhaps redefine, OSA from
the perspective of heart disease. Established definitions of
OSA are based simply on respiratory and neurophysiologic
parameters, but if the cardiovascular consequences of this
disease are the most important ones, then this disease may
be better defined by parameters such as heart rate, rhythm,
or blood pressure responses to these breathing events, rather
than the events themselves.
Finally, cardiologists have adapted better than most
physicians to the need to build an evidence base of efficacy
and cost-effectiveness for newer therapies in medicine.
Obstructive sleep apnea and the cardiovascular disorders
associated with it are all extremely common and we need to
establish cost-effective methods to screen for and treat
patients with OSA.
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